AD 219
Alternative Names: AD-219Latest Information Update: 14 Oct 2021
At a glance
- Originator Addpharma
- Class Antihyperglycaemics; Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Hypertension; Type 2 diabetes mellitus
Most Recent Events
- 14 Oct 2021 Early research in Hypertension in South Korea (unspecified route) prior to October 2021 (Addpharma pipeline, October 2021 )
- 15 Dec 2020 AD 219 is available for licensing as of 15 Dec 2020. http://www.addpharma.co.kr/
- 15 Dec 2020 Early research in Type 2 diabetes mellitus in South Korea (unspecified route) (Addpharma pipeline, December 2020)